Skip to main content
Journal cover image

Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.

Publication ,  Journal Article
Lopes, RD; Williams, JB; Mehta, RH; Reyes, EM; Hafley, GE; Allen, KB; Mack, MJ; Peterson, ED; Harrington, RA; Gibson, CM; Califf, RM ...
Published in: Am Heart J
September 2012

BACKGROUND: Edifoligide, an E2F transcription factor decoy, does not prevent vein graft failure or adverse clinical outcomes at 1 year in patients undergoing coronary artery bypass grafting (CABG). We compared the 5-year clinical outcomes of patients in PREVENT IV treated with edifoligide and placebo to identify predictors of long-term clinical outcomes. METHODS: A total of 3,014 patients undergoing CABG with at least 2 planned vein grafts were enrolled. Kaplan-Meier curves were generated to compare the long-term effects of edifoligide and placebo. A Cox proportional hazards model was constructed to identify factors associated with 5-year post-CABG outcomes. The main outcome measures were death, myocardial infarction (MI), repeat revascularization, and rehospitalization through 5 years. RESULTS: Five-year follow-up was complete in 2,865 patients (95.1%). At 5 years, patients randomized to edifoligide and placebo had similar rates of death (11.7% and 10.7%, respectively), MI (2.3% and 3.2%), revascularization (14.1% and 13.9%), and rehospitalization (61.6% and 62.5%). The composite outcome of death, MI, or revascularization occurred at similar frequency in patients assigned to edifoligide and placebo (26.3% and 25.5%, respectively; hazard ratio 1.03 [95% CI 0.89-1.18], P = .721). Factors associated with death, MI, or revascularization at 5 years included peripheral and/or cerebrovascular disease, time on cardiopulmonary bypass, lung disease, diabetes mellitus, and congestive heart failure. CONCLUSIONS: Up to a quarter of patients undergoing CABG will have a major cardiac event or repeat revascularization procedure within 5 years of surgery. Edifoligide does not affect outcomes after CABG; however, common identifiable baseline and procedural risk factors are associated with long-term outcomes after CABG.

Duke Scholars

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

September 2012

Volume

164

Issue

3

Start / End Page

379 / 386.e1

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Proportional Hazards Models
  • Postoperative Complications
  • Patient Readmission
  • Oligonucleotides
  • Myocardial Revascularization
  • Myocardial Infarction
  • Middle Aged
  • Kaplan-Meier Estimate
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lopes, R. D., Williams, J. B., Mehta, R. H., Reyes, E. M., Hafley, G. E., Allen, K. B., … Alexander, J. H. (2012). Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J, 164(3), 379-386.e1. https://doi.org/10.1016/j.ahj.2012.05.019
Lopes, Renato D., Judson B. Williams, Rajendra H. Mehta, Eric M. Reyes, Gail E. Hafley, Keith B. Allen, Michael J. Mack, et al. “Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.Am Heart J 164, no. 3 (September 2012): 379-386.e1. https://doi.org/10.1016/j.ahj.2012.05.019.
Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, et al. Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J. 2012 Sep;164(3):379-386.e1.
Lopes, Renato D., et al. “Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.Am Heart J, vol. 164, no. 3, Sept. 2012, pp. 379-386.e1. Pubmed, doi:10.1016/j.ahj.2012.05.019.
Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH. Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J. 2012 Sep;164(3):379-386.e1.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

September 2012

Volume

164

Issue

3

Start / End Page

379 / 386.e1

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Proportional Hazards Models
  • Postoperative Complications
  • Patient Readmission
  • Oligonucleotides
  • Myocardial Revascularization
  • Myocardial Infarction
  • Middle Aged
  • Kaplan-Meier Estimate